MedTrace Logo

Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment

NCT04053699 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2023-12-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to prospectively obtain reliable data on the bleeding and treatment pattern of patients with VWD undergoing on-demand treatment with a VWF-containing product over a period of 6 months. The data obtained will be used as a basis for historical comparisons with the bleeding and treatment pattern obtained from a clinical study on the efficacy of prophylactic treatment with a VWF/FVIII concentrate.

Conditions

  • Von Willebrand Diseases

Interventions

DRUG

Von Willebrand Factor-Containing Product

Active substances: VWF concentrates, VWF/FVIII concentrates, Cryoprecipitate VWF-containing products licensed in each participating country

Sponsors & Collaborators

  • Octapharma

    lead INDUSTRY

Principal Investigators

  • Cristina Solomon, MD · Octapharma

Eligibility

Min Age
66 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-25
Primary Completion
2021-01-31
Completion
2021-01-31
FDA Drug
Yes

Countries

  • United States
  • Belarus
  • Bulgaria
  • Croatia
  • Hungary
  • Lebanon
  • Russia
  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04053699 on ClinicalTrials.gov